Emricasan: Phase II started

Conatus began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 25 mg oral emricasan twice daily for 28 days in about 60 patients with severe alcoholic hepatitis. The Translational Research and Evolving Alcoholic Hepatitis Treatment (TREAT) consortium is conducting the trial. The consortium consists of the Mayo Clinic (Rochester, Minn.), Indiana University (Indianapolis, Ind.) and Virginia Commonwealth University (Richmond, Va.) in collaboration with NIH's National Institute on Alcohol Abuse and Alcoholism (NIAAA). ...